Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + chidamide + gemcitabine for first-line advanced or metastatic pancreatic cancer
ChiCTR2400079609Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, tucidinostat and gemcitabine in pancreatic cancer (PC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: safety and objective response rate. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimabtucidinostatgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400079609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079609.